SIAH ubiquitin ligases regulate breast cancer cell migration and invasion independent of the oxygen status

M Gordian Adam1,2, Sonja Matt1, Sven Christian2, Holger Hess-Stumpp2, Andrea Haegebarth2, Thomas G Hofmann1,*1, and Carolyn Algire2,*1

1Cellular Senescence Group; German Cancer Research Center DKFZ; Heidelberg, Germany; 2GTRG Oncology II; GDD; Bayer Pharma AG; Berlin, Germany

These authors equally contributed to this work.

Keywords: breast cancer, invasion, metastasis, migration, p27Kip1, SIAH ubiquitin ligases, seven-in-absentia, SIAH1, SIAH2, stathmin

Abbreviations: BrdU, bromodeoxyuridine; CAMKII, Ca2+/Calmodulin-dependent kinase II; CDK, Cyclin-dependent Kinase; DCC, deleted in colorectal cancer; DOX, Doxorubicin; EB3, Microtubule End-Binding protein 3; ER, estrogen receptor; HIF1α, Hypoxia-Inducible Factor 1α; ERK, Extracellular Signal-Regulated Kinase; HIPK2, Homeodomain-Interacting Protein Kinase 2; MEFs, mouse embryonic fibroblasts; N-CoR, nuclear receptor corepressor; PHD, prolyl-hydroxylase domain protein; PML, promyelocytic leukemia protein; PP1, protein phosphatase 1; Rb, retinoblastoma protein; SIAH, seven-in-absentia homolog; TRAF2, tumor necrosis factor receptor-associated factor 2; VEGF, vascular endothelial growth factor; VHL, von Hippel-Lindau protein.

Seven-in-absentia homolog (SIAH) proteins are evolutionary conserved RING type E3 ubiquitin ligases responsible for the degradation of key molecules regulating DNA damage response, hypoxic adaptation, apoptosis, angiogenesis, and cell proliferation. Many studies suggest a tumorigenic role for SIAH2. In breast cancer patients SIAH2 expression levels correlate with cancer aggressiveness and overall patient survival. In addition, SIAH inhibition reduced metastasis in melanoma. The role of SIAH1 in breast cancer is still ambiguous; both tumorigenic and tumor suppressive functions have been reported. Other studies categorized SIAH ligases as either pro- or antimigratory, while the significance for metastasis is largely unknown. Here, we re-evaluated the effects of SIAH1 and SIAH2 depletion in breast cancer cell lines, focusing on migration and invasion. We successfully knocked down SIAH1 and SIAH2 in several breast cancer cell lines. In luminal type MCF7 cells, this led to stabilization of the SIAH substrate Prolyl Hydroxylase Domain protein 3 (PHD3) and reduced Hypoxia-Inducible Factor 1α (HIF1α) protein levels. Both the knockdown of SIAH1 or SIAH2 led to increased apoptosis and reduced proliferation, with comparable effects. These results point to a tumor promoting role for SIAH1 in breast cancer similar to SIAH2. In addition, depletion of SIAH1 or SIAH2 also led to decreased cell migration and invasion in breast cancer cells. SIAH knockdown also controlled microtubule dynamics by markedly decreasing the protein levels of stathmin, most likely via p27Kip1. Collectively, these results suggest that both SIAH ligases promote a migratory cancer cell phenotype and could contribute to metastasis in breast cancer.

Background

SIAH proteins are evolutionary conserved RING-type E3 ubiquitin ligases emerging as critical regulators in both normal development and cancer. SIAH proteins exert their primary functions by targeting selected proteins for proteasomal degradation by polyubiquitination.1 Whereas initial reports pointed to a role in tumor suppression,2 most recent studies indicate that SIAH proteins, especially SIAH2, are tumorigenic proteins and promote tumor cell proliferation in several tissues, although the molecular mechanisms have not yet been fully elucidated. Increased expression of SIAH has been reported in different human cancers such as prostate, lung and breast.3-5 Recently SIAH has also emerged as a tumor-specific biomarker in pancreatic cancer.6 The Cancer Genome Atlas lists the SIAH2 gene as amplified in many human tumors (e.g., in 30% of lung squamous cell carcinoma).7,8 Both SIAH1 and SIAH2 were reported to increase proliferation of liver cancer cells9,10 and SIAH2...
expression was reported to promote tumor growth in head and neck tumors. SIAH inhibition approaches have produced promising results in preclinical mouse models of lung cancer, melanoma, and pancreatic cancer.13

Numerous substrates have been identified that mediate the tumor promoting effects of SIAH1 and SIAH2 in Ras, estrogen, DNA-damage, and hypoxia response pathways, as summarized in reference 15. Interestingly, SIAH proteins are central regulators of the hypoxic adaptation. The prolyl hydroxylase domain proteins PHD1, PHD2, and PHD3 mainly act to hydroxylate HIF1α, which is a prerequisite for its von Hippel-Lindau (VHL) protein-dependent degradation. SIAH targets the PHDs for degradation via ubiquitination, thus leading to stabilization of the transcription factor HIF1α, which in turn amplifies proangiogenic factors such as Vascular Endothelial Growth Factor A (VEGF-A) and thus induces tumor vascularization, tumor growth and metastatic potential. SIAH proteins also target the cell fate regulator Homeodomain-Interacting Protein Kinase 2 (HIPK2) for degradation, a critical event for full induction of hypoxia-induced genes that is also associated with decreased chemosensitivity of hypoxic cells. Numerous substrates have been identified that mediate polyubiquitination and degradation of more than a dozen of established tumor suppressors, including Numb, Promyelocytic Leukemia protein (PML), HIPK2, and Deleted in Colorectal Cancer (DCC).

Many studies on the function of SIAH proteins in cancer have been conducted in breast cancer cell lines, patient samples, or mouse models. Whereas high SIAH expression in patient samples was predictive for the progression of ductal carcinoma in situ to invasive breast cancer, SIAH inhibition has been shown to reduce tumor growth in a murine breast cancer model. It was recently reported that SIAH1 and SIAH2 genes were amplified in samples from breast cancer patients by 17% and 10%, respectively. Similar to other cancer entities, SIAH2 primarily shows tumorigenic functions in breast cancer: SIAH2 knockout mice show delayed tumor onset and reduced infiltration in a spontaneous mouse breast cancer model. SIAH2 silencing reduced breast tumor growth in vivo. It is upregulated in basal-like breast cancer and its expression correlates with increased tumor aggressiveness. The role for SIAH1 in breast cancer remains less well described. In contrast to other cancer types, only few reports identify SIAH1 as a pro-tumorigenic protein in breast cancer similar to SIAH2, most point to a tumor suppressor role for SIAH1 in breast cancer.

As high SIAH2 expression correlates with increased invasiveness and decreased overall patient survival in breast cancer,6,26,28 we aimed to determine if SIAH proteins play a role in breast cancer cell migration and metastasis. To date, the effects of SIAH inhibition, or silencing, on breast cancer metastasis or migration have not been reported; and also in other cancer types the general role of SIAH proteins in metastasis is not clear. For example, high SIAH2 expression correlated with metastasis in liver cancer, and SIAH inhibition strongly reduced metastasis in a syngeneic melanoma mouse model, yet anti-metastatic actions of SIAH1/2 have also been reported.37,38 Cancer cell migration and invasion are key components necessary for metastasis. Cell motility is mainly controlled by the Actin cytoskeleton, which provides the driving force at the leading edge of the cell, and the microtubule network that ensures rear retraction and controls protrusive and contractile forces. Actin and microtubule dynamics are highly cross-linked, regulating each other and being affected by adhesion and polarization. Both SIAH1 and SIAH2 were reported to promote migration of liver cancer cells,9,10 and SIAH1 silencing inhibited glioblastoma cell migration and invasion under hypoxia.41 Nevertheless, results from other groups indicate that SIAH1 exerts antimigratory activities in squamous cell carcinoma, neuronal cells, and mouse embryonic fibroblasts (MEFs).

In this study we re-examined the role of SIAH1 and SIAH2 in breast cancer cell apoptosis, migration, and invasion. Our results support a tumor promoting role for both SIAH1 and SIAH2 in breast cancer cells.

Results

Regulation of hypoxic adaptation by SIAH1/2 in breast cancer cells

Initially, we determined the expression of SIAH1 and SIAH2 in various breast cancer cell lines. Although to different levels, SIAH1 and SIAH2 are expressed in MCF10A breast epithelial cells as well as MCF7, T47D, MDA-MB-231, and MDA-MB-468 breast cancer cells (Fig. 1A). Since MCF7 cells showed strong protein expression of both SIAH1 and SIAH2, we researched the effects of SIAH1 and SIAH2 depletion primarily in this cell model. To silence SIAH1 and SIAH2 in MCF7, we used siRNAs that had been previously published to work both potently and selectively. Knockdown of SIAH1 and SIAH2 with these siRNAs was confirmed both on mRNA level (Fig. S1A) and protein level (Fig. 1B).

To investigate the impact of SIAH ligase silencing on signaling in breast cancer cells, we looked at protein levels of known SIAH substrates. First, we determined the protein levels of the Tumor Necrosis Factor (TNF) receptor-associated factor 2 (TRAF2), a well-known SIAH substrate involved in TNF receptor signal transduction. TRAF2 was previously published to be a substrate of SIAH2, but not of SIAH1; consistently we found increased TRAF2 levels upon silencing of SIAH2, but not SIAH1 (Fig. S2A).

The pro-tumorigenic actions of SIAH1 and SIAH2 have been attributed to the regulation of PHD proteins, of which PHD3 is most strongly regulated by SIAH. PHD3 levels were increased after silencing of either SIAH1 or SIAH2 (Fig. 1C). Consistently, HIF1α accumulation under hypoxic conditions (1% O2) was decreased in SIAH1 and SIAH2 silenced cells (Fig. 1D). In this regard, SIAH1 and SIAH2 showed redundant function in MCF7 breast cancer cells, as previously reported in other cell lines. To investigate the effects of SIAH knockdown...
downstream of HIF1α, we employed a cell line which expresses luciferase under control of a VEGF-promotor (HCT116–4xVEGF-Luc) to monitor HIF1α activity in a luciferase assay. It was confirmed that silencing of SIAH1 and SIAH2 had a comparable effect on the HIF downstream targets in this cell line as in MCF7 cells (Fig. S2B). Individual silencing of SIAH1, SIAH2, or in combination led to a significant decrease in VEGF promoter activation both under hypoxic and normoxic conditions (Fig. 1E).

SIAH1 and SIAH2 control cell proliferation and cell death in breast cancer cells

Based on the results presented in Figure 1 we concluded that SIAH1 and SIAH2 have similar functions in MCF7 breast cancer cells. We thus hypothesized that SIAH1 may have a tumor promoting role in breast cancer cells similar to SIAH2. If this is the case, silencing of SIAH1 should have a similar effect on breast cancer cell proliferation and apoptosis as silencing of SIAH2. To compare the role of both SIAH ligases in different types of breast cancer, SIAH1 and SIAH2 functions were assessed in luminal-like, hormone receptor positive MCF7 breast cancer cells, basal-like, triple-negative MDA-MB-468 breast cancer cells, and MCF10A mammary epithelial cells as a non-cancer control cell line. In these additional cell lines, SIAH1 and SIAH2 were also successfully silenced by RNAi transfection (Fig. S1B, C, E, F). Cell proliferation was decreased in all 3 cell lines upon silencing of SIAH1, SIAH2, or both (Fig. 2A). Comparable effects could also be observed under hypoxic conditions (1% O2) (Fig. 2B). These results show that SIAH1 silencing inhibits proliferation in breast cancer cells. It had been previously observed in MEFs, that SIAH2 mRNA transcription was increased under hypoxia, which could also affect the efficiency of SIAH silencing in the cell proliferation assays. Therefore we monitored if SIAH protein expression was altered in cell culture under hypoxic conditions; however, this was not the case (Fig. S2C).

We determined spontaneous apoptotic cell death in SIAH-silenced cells in comparison to control siRNA-treated cells. Knockdown of SIAH1 and SIAH2 significantly increased the fraction of apoptotic cells in MCF7 (Fig. 2C). Similar results were observed in cells grown under hypoxic conditions (Fig. 2D). The influence of SIAH ligases on apoptosis has been linked to their role in DNA-damage response. Together with HIPK2, a substrate of both SIAH1 and SIAH2, SIAH ligases promote recovery from DNA-damage. We cultivated the cells in presence of the DNA-damaging drug Doxorubicin, a chemotherapeutic drug widely used in adjuvant
breast cancer therapy. Doxorubicin treatment increased apoptosis in all cell lines tested (Fig. 2C-H). Cell death was even further increased in SIAH-silenced MCF7 cells. This could be detected when the cells were kept at 1% O₂ as well as under normoxic conditions (Fig. 2C, D). These results indicate that SIAH1 and SIAH2 can inhibit apoptosis in MCF7 cells, as it has been shown before in other cancer cell types. However silencing of SIAH1 and SIAH2 did not yield a significant increase in apoptosis in MDA-MB-468 or MCF10A cells (Fig. 2E-H), similar to what has been described for SIAH-deficient mouse embryonic fibroblasts. Also the effect of Doxorubicin was not further increased by SIAH1 or SIAH2 silencing in these cell lines, neither at normoxic nor hypoxic conditions.

Role of ER receptor status in SIAH-controlled sensitivity of breast cancer cells

A possible explanation why MCF7 cells are more sensitive to the SIAH knockdown is their hormone receptor status. In contrast to MDA-MB-468 and MCF10A cells, the MCF7 cell line is estrogen receptor (ER)-positive. ER signaling is elicited by estradiol, which is present in the MCF7 culture medium, and is negatively regulated by the Nuclear receptor Corepressor (N-CoR). Estradiol can inhibit apoptosis in MCF7 cells and activate SIAH2. Both SIAH1 and SIAH2 promote N-CoR degradation, thereby in turn increasing estrogen signaling. Under these conditions, ER signaling and SIAH form a positive feedback loop, inducing high SIAH2 upregulation in ER-positive breast cancer. We determined N-CoR protein levels and confirmed increased N-CoR protein expression upon silencing of SIAH1 or SIAH2 (Fig. S3A). Silencing of N-CoR with siRNA (Fig. S3B) did not markedly change the apoptosis levels in MCF7, MDA-MB-468, or MCF10A cells (Fig. S3C). Yet, N-CoR silencing partly rescued the fraction of apoptotic cells in MCF7 silenced for expression of SIAH1, SIAH2, or both (Fig. S3D). This could also be observed after stimulation with Doxorubicin (Fig. S3E), suggesting that the N-CoR silencing partly counteracts the effects of the SIAH knockdown. These results indicate that SIAH silencing stabilizes...
N-CoR and thereby decreases antiapoptotic ER signaling. This effect contributes to the increased apoptosis observed upon SIAH silencing in ER-positive breast cancer cells.

To elaborate on the hypothesis that the ER receptor status is relevant, we repeated the cell death assays with another ER-positive breast cancer cell line, T47D.\textsuperscript{55} Also in these cells, SIAH1 and SIAH2 were silenced successfully (Fig. S1D, G). Similar to MCF7 cells, both baseline apoptosis, as well as Doxorubicin-induced apoptosis, were increased by silencing of SIAH2 both under normoxic and hypoxic conditions (Fig. S4A, B). The effect of SIAH1 silencing did not reach significance; it could be speculated that this might be connected to the lower endogenous SIAH1 expression level compared to MCF7 cells (Fig. S1A). Additional silencing of N-CoR partly rescued the fraction of apoptotic cells in T47D silenced for expression of SIAH1, SIAH2, or both (Fig. S4C, D), similar as in MCF7 cells.

Together the results show that knockdown of SIAH1 or SIAH2 led to increased apoptosis in ER-positive breast cancer cells, and reduced cell proliferation and hypoxic adaptation in both ER-positive and ER-negative breast cancer cells. These results point to a tumor promoting role for SIAH1 in breast cancer similar to SIAH2.

Silencing of both SIAH ligases inhibits breast cancer cell migration and invasion

As the observations in breast cancer patients point to a role for SIAH ubiquitin ligases in breast cancer metastasis,\textsuperscript{28} we hypothesized that SIAH ligases promote breast cancer cell migration. We induced a defined gap in a monolayer of MCF7 cells and calculated the cell migration speed from the gap closure after 24 h. When SIAH1, SIAH2, or both were silenced, gap closure was markedly decreased (Fig. 3A). Comparable effects were found in MDA-MB-468 and MCF10A cells. Quantification of the migration velocity shows that silencing of either SIAH ubiquitin ligase is sufficient to significantly inhibit cell migration (Fig. 3B). This was also observed under hypoxia to a comparable extent (Fig. 3C). To validate these results, cell migration was also assessed in a secondary assay. Instead of quantifying random cell motility, directed cell migration toward a chemical stimulus was measured in a modified Boyden chamber assay. This assay revealed a significant reduction in chemotaxis upon silencing of SIAH1 or SIAH2, in all 3 cell lines tested (Fig. 3D).

Next, cell invasion was assessed in a transwell assay in which the cells migrated through a coating of basal membrane extract. The basal membrane is a continuous, sheet-like extracellular matrix between endothelial, epithelial, muscle, or neuronal cells and the adjacent stroma, and represents a first boundary for invading cancer cells.\textsuperscript{64} Silencing of SIAH1 or SIAH2 signific-
cantly decreased invasion of MCF7, MDA-MB-468, or MCF10A cells through the basal membrane extract (Fig. 3E). To confirm this result, we also performed a transendothelial migration assay, in which the cells invade through a monolayer of endothelial cells, mimicking cancer cell intravasation into blood vessels. Transmigration of breast cancer cells was markedly reduced when SIAH1 or SIAH2 was silenced (Fig. S5). Together these results indicate that silencing of both SIAH1 and SIAH2 inhibits breast cancer cell migration, adding to the effects on proliferation, apoptosis, and hypoxic adaptation.

**SIAH ligases control the expression of the microtubule regulator stathmin**

Unexpectedly, SIAH1 and SIAH2 significantly affect proliferation, apoptosis, and migration under both normoxic and hypoxic conditions to a comparable extent, suggesting that PHD proteins and the hypoxia-activated HIF1α signaling pathways are not the main drivers of the SIAH-mediated signaling effects. To this end, we analyzed potential links between SIAH and known migration regulators. Interestingly, SIAH2 induces the ubiquitination and degradation of Sprouty2, a negative regulator of Ras signaling.65 The small GTPase Ras activates many downstream signaling pathways, regulating cell migration by controlling Actin polymerization via Myosin Light Chain phosphorylation and proliferation through the Raf-MEK-MAPK pathway.66 SIAH ligases are also linked to microtubule dynamics via 2 substrates: p27Kip144 and the Microtubule Plus End-Binding protein 3 (EB3).67 p27Kip1 is an important regulator of cyclin-dependent kinases (CDKs) that also regulates microtubule polymerization.69 Increased p27Kip1 expression inhibits cancer cell migration by modifying microtubule dynamics in a complex with the central microtubule regulator stathmin,70 a phosphoprotein that regulates microtubule destabilization, cell cycle control,71 and cell migration.72 It has been proposed that p27 might also control stathmin expression:72 by inhibition of CDKs, p27Kip1 inhibits the phosphorylation of the Retinoblastoma (Rb) protein.73 Phosphorylated Rb is no longer able to inhibit the activity of the transcription factor E2F1,74 which drives stathmin expression.75,76

We detected Sprouty2 accumulation in MCF7 upon silencing of SIAH2, but not of SIAH1 (Fig. 4A), confirming previous reports in other cell lines.77 Consistently we found that phosphorylation of the Extracellular Signal-Regulated Kinase (ERK) 1/2 was reduced upon silencing of SIAH2, but not SIAH1, indicating decreased Ras activation. Therefore, this pathway might contribute to the effects observed, but it was not sufficient to explain why SIAH1 silencing also decreased cell migration and invasion.

Immunoblot analysis verified that both p27Kip1 and EB3 are affected by SIAH silencing in MCF7 breast cancer cells (Fig. 4B). Whereas EB3 expression was moderately increased by SIAH2 knockdown, p27Kip1 expression was markedly increased by silencing of either SIAH1 or SIAH2. These results indicate that p27Kip1 is not merely a SIAH1 substrate as previously shown,44 but presumably also one of SIAH2.

p27Kip1 is known to block the activating phosphorylation of several CDKs, one of which is CDK6.78 Downstream of p27Kip1, we determined the protein levels of total and phosphorylated CDK6 in MCF7 cells (Fig. 4C). CDK6 phosphorylation at tyrosine 24 was markedly decreased upon silencing of SIAH1 and SIAH2, while the total CDK levels remained unaltered. This indicates reduced CDK activity, which is consistent with increased p27Kip1 expression. Next, we determined the phosphorylation status of the CDK substrate Rb. Rb phosphorylation at serines 780, 807, and 811 inhibits sequestration of the E2F1 transcription factor.74 Our results show that Rb phosphorylation at these sites was prominently decreased upon SIAH1 or SIAH2 silencing. Total Rb protein levels remained largely unaltered. Downstream of Rb and E2F1, stathmin protein levels were markedly decreased after depletion of SIAH1 or SIAH2 (Fig. 4C), which was in line with the reduction in cell motility.

Stathmin phosphorylation can interfere with stathmin activity,71 and it has been suggested that this might be influenced by p27Kip1 as well.72 Analysis of stathmin phosphorylation revealed a complex regulation in response to SIAH silencing (Fig. 5A). The amount of serine 38-phosphorylated stathmin was not profoundly altered. In contrast, stathmin phosphorylation at serine 16 was decreased, pointing toward increased stathmin activity. Although the Ca2+/Calmodulin-dependent Kinases II and IV (CAMKII and IV) were proposed as the main kinases for stathmin activity regulation,79,80 4 additional kinases also phosphorylate Stathmin at serine 16: Aurora B kinase,81 cAMP-dependent protein kinase (PKA-C),82,83 p21-activated kinase 1 (PAK1),84 and Ribosomal protein S6 kinase α-3 (RSK2).85 We determined the activity of these kinases by testing the phosphorylation status. Exclusively phosphorylation of CAMKII β, which is responsible for 65% of the CAMKII activity,86 was markedly decreased (Fig. 5B-D), suggesting that stathmin phosphorylation at serine 16 was reduced due to decreased CAMKII activity upon SIAH silencing.

Next we determined protein levels of acetylated α-Tubulin as a measure of non-dynamic, stable microtubules.87,88 Elevated levels of acetylated α-Tubulin upon silencing of SIAH1 or SIAH2 in MCF7 cells (Fig. 4D) indicated reduced stathmin activity and increased microtubule polymerization and stability. In line with a previous report showing that stathmin activity promotes AKT activity,89 AKT phosphorylation was decreased upon SIAH silencing (Fig. 4D), further confirming that overall stathmin activity is negatively regulated by SIAH silencing. To investigate if CDK inhibition is sufficient to influence stathmin protein levels and thereby microtubule stability, we treated MCF7 cells with the pan-CDK inhibitor Roniciclib (BAY1000394). CDK inhibition resulted in decreased stathmin expression and increased α-Tubulin acetylation (Fig. 5E), which supports the hypothesis that SIAH ligases control stathmin expression and cell migration via p27Kip1.

To determine if alterations in microtubule turnover are visible looking directly at microtubules, we stained MCF7 cells for α-Tubulin and acetylated α-Tubulin (Fig. 4E). While total microtubule amount and appearance remained virtually
unchanged, silencing of either SIAH1 or SIAH2 led to increased tubulin acetylation also in this setting, indicating increased microtubule stability.

Collectively, our results suggest that SIAH ligases promote cancer cell migration and invasion, at least in part, by inducing the degradation of p27\(^{kip1}\) to promote microtubule depolymerization by increased stathmin expression.

**Discussion**

Depletion of SIAH1 and SIAH2 affects hypoxic adaptation, proliferation, migration and cell death

This report shows that SIAH1 assumes a tumor-promoting role in breast cancer cells similar to SIAH2 and that both ubiquitin ligases affect cell migration. We show that, like SIAH2, SIAH1 silencing reduces hypoxic adaptation, proliferation and migration, and increases apoptosis and susceptibility to DNA-damaging chemotherapeutics in MCF7 breast cancer cells. This is in line with previous studies, which report that SIAH1 reduced PHD3 protein levels similar to that observed with SIAH2 in breast cancer\(^{24}\) and promotes the breast cancer stem cell phenotype.\(^{29}\) However it is in conflict with other reports that found SIAH1 has proapoptotic\(^{32,34,36}\) and antiproliferative\(^{30,32}\) properties in breast cancer cells. This discrepancy cannot be fully resolved, however our results show that the effects of SIAH1 silencing, especially with regards to apoptosis, are cell-line dependent (Fig. 2C-F). Additional factors, such as the hormone receptor status of the cell line and estrogen concentration of the cell culture media seem to have major impact on the biological effects of SIAH silencing. Our results suggest that SIAH silencing promotes apoptosis in estrogen-dependent MCF7 and T47D cells in part due to the accumulation of the estrogen signaling repressor N-CoR, and this can be partially rescued by N-
CoR silencing. Breast cancer cell lines also show marked variation regarding SIAH1 and SIAH2 expression levels (Fig. 1A), which might influence sensitivity to SIAH knockdown as well. At least for SIAH2, this might be linked to estrogen signaling promoting SIAH2 expression. In MCF7 cells cultured without estrogen, the SIAH2 protein levels were found to be below the expression levels of MDA-MB-468 and MDA-MB-231 cells.

Our results indicate that silencing of SIAH1 and SIAH2 inhibits both random cell motility and chemotactic migration in MCF7 and MDA-MB-468 breast cancer cells. The promigratory actions of SIAH ligases contribute to their tumor promoting role such as revealed in studies on hepatocellular carcinoma and glioblastoma. Also the invasive potential of breast cancer cells was significantly decreased upon SIAH1 and SIAH2 silencing. Notably, MCF7 cells and MDA-MB-468 cells represent different types of breast cancer cells and also differ in the invasive behavior. MCF7 cells have a pure luminal phenotype and are characterized by weak invasive capacity, whereas MDA-MB-468 cells show more mesenchymal characteristics and a high invasive capacity.

The tumor promoting effects of SIAH ligases do not require hypoxic conditions

The tumor promoting effects of SIAH ligases have often been attributed to their substrates of the PHD family and subsequent influence on HIF1α activity. However, our results indicate that hypoxia is not a prerequisite for the effect of SIAH silencing on proliferation, migration and apoptosis since breast cancer cells grown under normoxic conditions show comparable effects on SIAH depletion. Thus SIAH ligases relay the tumor promoting effects through regulating signaling pathways different from the SIAH-PHD-HIF1α signaling axis. Moreover it has been shown that PHD2, which is hardly affected by SIAH, mainly controls HIF1α stability under hypoxia, while PHD1 and 3, which are profoundly degraded after SIAH-dependent ubiquitination, have a stronger influence on HIF1α stability under mild or moderate hypoxia (5-10% O2).

Analysis of cell migration reveals novel mechanistic insight into tumor promoting effects of SIAH ligases

This is the first report to show that silencing of SIAH ligases inhibits the expression of the central microtubule regulator stathmin. Stathmin, also called Oncoprotein 18, is highly over-expressed in different cancer entities and its depletion slows down proliferation and increases apoptosis. It is likely that SIAH controls migration and invasion in part through its influence on stathemin and its interaction partner p27Kip1. Stathmin binds α/β-tubulin heterodimers to facilitate the depolymerization of microtubules and can also inhibit microtubule polymerization. Consistently, silencing/inhibition of stathmin leads to increased tubulin acetylation, which slows down cell motility, while high stathmin protein levels inhibit tubulin acetylation. Previous reports demonstrated that the SIAH substrate p27Kip1 inhibits stathmin, promoting tubulin stability and inhibiting migration, suggesting that SIAH ligases exert their effects on migration and invasion via this axis. Of note, stathmin might also regulate p27Kip1 protein levels, presumed through their common interaction partner Kinase-interacting stathmin (KIS).

Similar to the SIAH ligases, there have been conflicting reports on the influence of stathmin on migration. Microtubule destabilization was described as promoter of cell motility and migration in several studies reporting that stathmin has promigratory and proinvasive activities and promotes chemotherapy resistance. However, the destabilization of microtubule plus ends at the cell cortex can also inhibit directional cell migration, suggesting that stathmin might also inhibit migration under certain conditions. Uncovering the roles of stathmin is further complicated by the observation that proliferation effects seem to depend on the phosphorylation status while effects on migration rely on protein expression levels only. The role of the p21-related p27Kip1 in migration is under debate, although the many reports point to an antimigratory activity. One might speculate that the effect of SIAH ligases on migration diverges in different cell lines because their downstream effectors p27Kip1 and stathmin fulfil alternative roles in different cell lines. Although SIAH silencing negatively regulated total stathmin levels, this was opposed by decreased phosphorylation at serine 16, a major target of CAMKII. Potentially, the observed reduction in CAMKII activity is a direct consequence of SIAH silencing. CAMKII activity is controlled by protein phosphatase 1 (PP1), and some of the PP1 subunits have been described as an interaction partners or substrates of SIAH2. Therefore, it is possible that SIAH ligases regulate CAMKII phosphorylation via ubiquitination and degradation of PP1 subunits. It also appears plausible that the observed reduction in stathmin phosphorylation is independent of SIAH and part of a compensatory cellular response to facilitate the balance of microtubule dynamics. However, the effect on stathmin phosphorylation cannot compensate for the decrease in stathmin expression by SIAH silencing, as evident by increased tubulin acetylation and decreased cell migration and invasion.

The connection between SIAH ligases and stathmin provides a link to the SIAH knockdown effects on migration, invasion, proliferation, and apoptosis. A summary of the pathway suggested by our results is depicted in Figure 5. Still we assume that this pathway is only one of several contributing effector pathways downstream of SIAH1 and SIAH2. Others have shown previously that a number of different SIAH substrates also play a major role regarding the tumor promoting effects of SIAH family members.

In summary, our study supports previous findings that classify SIAH2 as a tumor promoting protein in breast cancer and, furthermore, strongly suggests that SIAH1 assumes a similar role. Our results show that both SIAH1 and SIAH2 promote breast cancer cell migration and invasion, 2 hallmarks of metastatic cancer subtypes. Along with previous findings that SIAH2 expression in breast cancer patients correlates with increased cancer invasiveness and decreased overall survival, and that SIAH inhibition reduced metastasis in a melanoma mouse model, these results indicate that SIAH ligases might very well promote breast cancer cell metastasis. The involvement of p27Kip1 and stathmin...
downstream of SIAH1/2 points to a novel component that is likely to contribute to the SIAH mechanism of action in metastasis. However, detailed future studies are required to further elucidate the role of SIAH1 and SIAH2 in breast cancer metastasis and to reveal additional regulation mechanisms downstream of SIAH.

As approximately 90% of all cancer-related mortalities are due to metastases,121 it could be beneficial to inhibit SIAH ligases in anticancer therapy. As SIAH1 and SIAH2 are similar in amino acid sequence and molecule structure,122 it would be difficult to find inhibitors selective for one isoform. However, this might not be required as our study shows that both human SIAH forms have similar roles in breast cancer. Further investigations are required to clarify whether SIAH ubiquitin ligases represent promising targets for anticancer therapy.

Materials & Methods

Cell culture

MCF7 cells (ATCC® HTB22™) were grown in RPMI 1640 (1x) medium without phenol red (Gibco, Cat.No. 32404-014) supplemented with 10% fetal bovine serum (FBS Superior; Biochrom, Cat.No. S0615), 1x10⁻⁷ M β-estradiol (Sigma, Cat.No. E2257), 10 μg/ml human recombinant insulin (Biochrom, Cat. No. K3620) and 5 ml 100x GlutaMAX™-I (Gibco, Cat.No. 35050-038). MDA-MB-468 cells (ATCC® HTB-132™) were grown in RPMI 1640 medium (1x) + GlutaMAX™-I (Gibco, Cat.No. 61870-010) supplemented with 10% FBS. MCF10A (ATCC® CRL10317™) were cultured in DMEM/F-12 (1:1) (1x) medium (Gibco, 11039-021) supplemented with 5% HI Horse Serum (Gibco, Cat.No. 26050-088), 9.5 μg/ml hydrocortisone (Biochrom, Cat.No. K3520), 20 ng/ml human recombinant EGF (Sigma, Cat.No. E9644), and 10 μg/ml human recombinant insulin. T47D (ATCC® HTB-133™) were cultured in RPMI 1640 (1x) medium + GlutaMAX™-I supplemented with 10% FBS, 1x10⁻⁷ M β-estradiol, and 10 μg/ml human recombinant insulin. HCT116-4xVEGF Luc had previously been generated by stably transfecting HCT-116 cells (ATCC® CCL-247™) with pGL2-TK-HRE, containing the luciferase reporter gene under control of 4 copies of a HIF response element (HRE) derived from the human VEGF promoter. 50 They were cultured in McCoy’s 5a Medium Modified (1x) + GlutaMAX™-I (Gibco, Cat.No. 36600–021), supplemented with 10% FBS. Primary human umbilical vein endothelial cells (HUVEC) were obtained from Lonza (Cat.No. C2519AS) and cultured in endothelial cell growth medium (Lonza, Cat.no. CC-3162). They were used for assays only between passages 3 and 6.

Where indicated, cells were treated with the pan-CDK inhibitor Roniciclib (BAY 1000394)123 (10nM or 30 nM) for 48 h. siRNAs

The following previously published siRNAs were employed: SIAH1 siRNA (a), custom siRNA (Dharmacon, GATAGGAA-CACGGCAAGCAA);20,45 SIAH2 siRNA a, On-Target plus SMARTpool (Dharmacon, Cat.No. L-006561-00);47 SIAH2 siRNA b, siGenome SMARTpool (Dharmacon, Cat.No. M-006561-02);46 AllStars negative Control siRNA (Qiagen, Cat. No. 1027280).

For the SIAH1/2 double knockdown, SIAH1 siRNA and SIAH2 siRNA a were employed.

Antibodies and immunoblots

Antibodies were obtained from the following sources: anti-β-Actin antibody [AC-74] (A5316), anti-Siah2 antibody [clone Siah2-369] (S7945) from Sigma-Aldrich; anti-Cdk6 (phospho
Y24) antibody (ab131469), anti-EB3 antibody [KT36] (ab53360), anti-GAPDH antibody [6C5] (ab8245), anti-Sprouty 2 mouse antibody (ab60719) from abcam; acetyl-alpha- Tubulin (Lys40) (D20G3) antibody (#5335), phospho-Akt (Ser473) (D9E) antibody (#4060), Akt antibody (#9272), CDK6 (DCS83) Mouse mAb (#3136), phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) antibody (#9101), p44/42 MAPK (Erk1/2) antibody (#9102), p27 Kip1 (D69C12) XP® Rabbit mAb (#3686), Rb (4H1) Mouse mAb (#9309), phospho-Rb (Ser780) antibody (#9307), phospho-Rb (Ser807/811) antibody (#9308), Stat3/4 antibody (#3352) from Cell Signaling Technology; SIAH-1 antibody [N-15] (sc-5505) from Santa Cruz; purified mouse anti-human HIF-1α clone 54/HIF-1α (RUO) (610959) from BD Biosciences; PHD3/HIF Prolyl Hydroxylase 3 antibody (NB100-139) from Novus Biologicals.

Cells were harvested in Pierce® RIPA Buffer (Thermo Scientific, Cat. No. #89901) with protease inhibitor (Complete ULTRA Tablets, Roche, Cat. No. 04906837001) and phosphatase inhibitor (PhosSTOP, Roche, Cat. No. 05892790101). Protein concentration was assessed with a BCA protein assay kit (Novagen, Cat. No. 71285-3). Proteins were separated by electrophoresis on 4-12% Novex® NuPAGE 4-12% Bis-Tris Gel (Life Technologies, Cat. No. NP0335BOX) and transferred to nitrocellulose membranes (Novex® iBlot® Transfer Stacks, Life Technologies, Cat. No. IB301001) as stated in the manufacturer’s protocol. Membranes were blocked with 5% skim milk in 0.5% Tween 20 in TBST and stained with primary antibodies at 4°C overnight. The membrane was washed and incubated with IRDye®-conjugated secondary antibody (LI-COR Biosciences, Cat.Nos. 925-32214 (IRDye® 800CW Donkey anti-Goat IgG (H + L)); 925-32210 (IRDye® 800CW Goat anti-Mouse IgG (H + L)); 925-32211 (IRDye® 800CW Goat anti-Rabbit IgG (H + L)); 925-32219 (IRDye® 800CW Goat anti-Rat IgG (H + L)); 925-68070 (IRDye® 800RD Goat anti-Mouse IgG (H + L))) for 1 h at room temperature. Signal detection was done in an Odyssey Infrared Imager (LI-COR Biosciences).

Apoptosis assay

Apoptosis was quantified with the Cell Death Detection ELISA PLUS (Roche, Cat. No. 1177425001) according to the manufacturer’s protocol. Briefly, following siRNA transfection (after 24 h) the cells were counted and 10^4 cells per well were seeded in a 96 well plate in growth medium as triplicates. After 4 h, 10 µl of growth medium with or without Doxorubicin was added (final concentrations 0, 0.1, or 1 µM). The cells were incubated for 18 h, then lyzed and centrifuged. The nucleosomes in the supernatant were then immediately quantified in the ELISA.

Luciferase assay

HIF target gene expression was monitored in a luciferase assay using the steadyline plus™ system (Perkin Elmer, Cat. No. 6066751) according to the manufacturer's protocol. Briefly, HCT116-4xVEGF+Luc cells were seeded and transfected in a 24 well plate. 48 h after transfection, the medium from all wells was pooled and a defined volume redistributed to the wells. The same volume steadyline plus reagent was added, the plate was protected from light and shaken gently for 15 min. From each well triplicates of 100 µl were transferred to a white 96 well plate (Nunc, Cat.No. 437796) and luminescence was measured in a Tecan infinite M200 PRO reader with Tecan i-control™ software.

To take into account that the different siRNAs have differential effects on cell viability, each plate was generated as a duplicate. The second plate was used for cell quantification with the CellTiter-Blue® Cell Viability assay (Promega, Cat.No. G8081) according to the manufacturer’s protocol. Results from the luciferase assay were normalized to the cell viability.

Proliferation assay

Cell proliferation was determined by 5-bromodeoxyuridine (BrdU) incorporation (Cell Proliferation ELISA, Roche, Cat. No. 1164729001) according to the manufacturer’s protocol. Epithelial cells were transfected with siRNAs. After 24 h the cells were counted and 7500 cells per well were seeded in a 96 well plate in growth medium as quintuplicates. After 24 h, BrdU was added for 2 h and newly synthesized DNA was detected with an enzyme-linked BrdU antibody.

Migration & Invasion assays

Cell motility was assessed with a wound healing assay as previously described124 in the presence of 10 µg/ml mitomycin C (Sigma, Cat.No. M4287) to block proliferation. µ-Dish 35 mm high Culture-Inserts ibiTreat (ibidi, Cat.No. 80209) were placed in a 24 well plate coated with rat tail collagen I (Life Technologies, Cat.No. A1048301). Following siRNA transfection (after 24 h), cells were trypsinized and 600,000 cells/ml were suspended in growth medium. Of this suspension, 100 µl were placed in each insert half. After 24 h, the inserts were removed and the gap width was measured at the indicated time points. The migration rate was calculated as the velocity of the moving cell front in µm/h.

Chemotaxis was determined with a modified Boyden chamber assay (CytoSelect 96-well Cell Migration Assay, Cell Biolabs Inc., Cat.No. CBA-106-CB). 24 h after the RNAi transfection, the cells were starved overnight in medium lacking FBS, counted, and seeded into the upper chambers in FBS-free medium containing 10 µg/ml mitomycin C. The lower chambers were filled with full medium containing 10% FBS as a stimulus and mitomycin C. Cells were allowed to migrate for 24 h, and then migratory cells were dissociated from the membrane, lysed and quantified with CyQuant® GR Fluorescent Dye.

Cell invasion was assessed in a transwell assay (CytoSelect 96-well Cell Invasion Assay, Cell Biolabs Inc., Cat.No. CBA-112-CB). 24 h after the RNAi transfection, the cells were starved overnight in medium lacking FBS. The transwells coated with basal membrane extract were rehydrated in serum-free medium for 1 h. The cells were counted and seeded into the transwell in FBS-free medium containing 10 µg/ml mitomycin C. The lower wells were filled with full medium containing 10% FBS as a stimulus and mitomycin C. Cells were allowed to invade through the basal membrane extract for 24 h, and then invasive cells were
dissociated from the membrane, lysed and quantified with CyQuant® GR Fluorescent Dye.

**Immunofluorescence staining**

Cells were seeded on glass cover slips precoated with Poly-D-lysine hydrobromide (Sigma, Cat.No. P6407) 24 h after siRNA transfection. Following an incubation time of 24 h, the cells were fixed with 4% formaldehyde + 0.1% glutaraldehyde and permeabilized with 0.1% saponin. α-Tubulin and acetylated α-Tubulin were localized using α-Tubulin (DM1A) Mouse mAb (#3873, 1:4000), or acetyl-α-Tubulin (Lys40) (D20G3) antibody (#5335, 1:800; both from Cell Signaling Technology), respectively. Cy3-conjugated Goat Anti-Rabbit IgG (1:50, Jackson ImmunoResearch, Cat.No. 111-165-144) and Goat Anti-Mouse IgG (DyLight 488) preadsorbed (1:50, Thermo Scientific, Cat.No. 35502) were used as secondary antibodies. Nuclei were stained with Hoechst 33342 (1:1000, Molecular Probes, Cat.No. H1399) and slides were mounted with FluorSave Reagent (Calbiochem, Cat.No. 345789). Images were taken with a Zeiss laser confocal microscope (LSM700) at 63x magnification.

**Statistical analysis**

Results are expressed as means plus standard deviations unless stated otherwise. Comparisons between groups were analyzed using an Ordinary one-way ANOVA. Multiple comparisons were corrected with Dunnett’s test. Probability values smaller than 0.05 were considered significant.

**Disclosure of Potential Conflicts of Interest**

S. Christian, H. Hess-Stumpf, A. Hägebarth, and C. Algire are full-time employees at Bayer Pharma.

**Acknowledgments**

We thank J. Pastorek & S. Pastoreková, Institute of Virology, Slovak Academy of Sciences, Bratislava, for providing the Carboxic Anhydrase IX monoclonal antibody, and Gerhard Simeister, Bayer Pharma AG, Berlin, for providing the pan-CDK inhibitor. We thank the scientists of the GTRG Oncology II, GDD, Bayer Pharma AG, and the Research Review Committee of the German Cancer Research Center – Bayer HealthCare Alliance, especially Ruth Wellenreuther, for many fruitful discussions.

**Supplemental Material**

Supplemental data for this article can be accessed on the publisher’s website.
22. Fanelli M, Fantozzi A, De Luca P, Caprodossi S, Israels H, Faille A, Linares-Cruz G, Matsuzawa S, Lazar MA, Pelicci PG, Minucci S. Identification of a Src tyrosine kinase/SIAH2 E3 ubiquitin ligase pathway that regulates hypoxic and genotoxic signaling pathways. J Mol Cell Biol 2012; 4:316-30; PMID:22878263; http://dx.doi.org/10.1039/jmbf0674.

23. Sarkar TR, Sharani S, Wang J, Pawar SA, Cantwell CA, Johnsson PF, Mortkow DK, Wang JM, Sterneck E. E3 ubiquitin ligase SIAH2 is a promising anticancer target. Cell Cycle 2014; 32:30-32; PMID:23037579; http://dx.doi.org/10.1186/1476-4598-10-57.

24. Hallahal H, Frew JI, Laine A, Janes PW, Relaix F, Eisinghhaus P, Heiser I, Santos J, Michailovski JK, Trivedi N, Howell D, Yang Y, Tong Y, Ronai Z, Cullinane C, et al. Vascular normalization under metabolic stress. Cell 2011; 145:447-63; PMID:21417703; http://dx.doi.org/10.1016/j.cell.2011.05.037.

25. Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H, Ha G, Yap D, Farahani H, et al. The expression of the ubiquitin ligase SIAH2 and its association with the natural history of the tumor. Oncogene 2009; 28:2590-2599; PMID:19543318; http://dx.doi.org/10.1038/ons.2009.156.

26. He JT, Fokas E, You A, Engelhardt-Caballero R, An HX. Siah1 proteins enhance radiosensitivity of human breast cancer cells. BMC Cancer 2010; 10:403; PMID:20682032; http://dx.doi.org/10.1186/1471-2407-10-403.

27. Ma B, Chen Y, Chen L, Cheng H, Mu C, Li J, Gao R, Song J, Zhang T, Chi D, Guan K, et al. The expression of miR-107 inhibits tumor growth in a nude mouse model of triple-negative breast cancer. Mol Carcinog 2010; 49:440-9; PMID:20088235.

28. Jansen MP, Ruigrok-Ritstier K, Dorssers LC, van Staa XL, Zhao J, Lu YY, Zhu JJ, Wang EH. E3 ubiquitin ligase function. Oncogene 2009; 28:289-96; PMID:19772588; http://dx.doi.org/10.1111/j.1349-7006.2009.01339.x.

29. Zhang L, Ma P, Sun LM, Han YC, Li BL, Mi XY, Wang CX, et al. The expression of SIP regulates p27(kip1) stability and cell migration in breast cancer cells. Mol Endocrinol 1999; 13:2122-30; PMID:10194504; http://dx.doi.org/10.1210/mcr.13.11.2122.

30. Bruzzoni-Giovanelli H, Faille A, Linares-Cruz G, Matsuzawa S, Lazar MA, Pelicci PG, Minucci S. Siah1 signaling between SIAH2 and DYRK2 controls hypoxic and genotoxic signaling pathways. J Mol Cell Biol 2012; 4:316-30; PMID:22878263; http://dx.doi.org/10.1039/jmbf0674.

31. Perez M, Garcia-Limon C, Zapico I, Marina A, Schmitz ML, Munoz E, Calafat MA. Metastatic regulation by hypoxia: interference with angiotensin signaling in breast cancer cells. Mol Cancer Biol 2012; 4:316-30; PMID:22878263; http://dx.doi.org/10.1039/jmbf0674.

32. Merino MJ, et al. Analyses of resected human brain stem cell phenotype. Oncotarget 2014; 5:12509-27; PMID:25020996; http://dx.doi.org/10.1634/theoncologist.10-10-780.

33. Tuynder M, Susini L, Prieur S, Besse S, Fiucci G, Amron R, Telemaran A. Biological models and genes of tumor reversion: cellular reprogramming through tp53/CTCF and SIAH1. Proc Natl Acad Sci U S A 2002; 99:19445-50; PMID:12395945; http://dx.doi.org/10.1073/pnas.222470799.

34. Shi H, Zheng B, Wu Y, Tang Y, Wang L, Gao Y, Zhang Y, et al. A fusion protein of the estrogen receptor beta and hyperphosphorylation and cell migration by controlling the molecular basis of Siah1 and Siah2 E3 ubiquitin ligase substrates. PloS One 2014; 9:e105547; PMID:25202994; http://dx.doi.org/10.1371/journal.pone.0105547.
79. le Gouvello S, Manceau V, Sobel A. Serine 16 of Aurora B is required for microtubule polymerization, providing a pro-invasive advantage to metastatic cancer cells. Poster presented at: AACR Annual Meeting 2014, April 5-9 2014. San Diego, CA.

80. Perdiz D, Mackeh R, Pous C, Baillet A. The ins and outs of tubulin acetylation: more than just a post-translational modification? Cell Signalling 2011; 23:763-71; PMID:20940043; http://dx.doi.org/10.1016/j.cellsig.2010.10.014

81. Schulze E, Asai DJ, Bulinski JC, Kirschner M. Post-translational modification and microtubule behavior. J. Cell Biol. 1987; 107:499-516; PMID:35316248; http://dx.doi.org/10.1083/jcb.105.5.2167

82. Akhtar J, Wang Z, Zhang ZP, Bi MM. Lentiviral-mediated RNA interference targeting stathmin1 gene. Cell Cycle 2005; 4(17):2899-902; PMID:16207115; http://dx.doi.org/10.1089/ccl.2005.4.2899

83. Gradin HM, Larsson N, Marklund U, Gullberg M. Dual mechanisms for the distinct cell cycle effects and differentiation programs of N-CoR-regulated genes. Proc Natl Acad Sci U S A 2000; 97:1333-38; PMID:10688801; http://dx.doi.org/10.1073/pnas.97.11.1333

84. Carney BK, Caruso Silva V, Cassimter L. The microtubule cytoskeleton is required for a G2 cell cycle delay in cancer cells lacking stathmin and p53. Cancer Res. 2012; 72:278-89; PMID:22407961; http://dx.doi.org/10.1002/cncr.25989

85. Alli E, Yang JM, Hain WT. Silencing of stathmin induces tumor-suppressor function in breast cancer cell line MCF-7 but has little effect on MDA-231 or MCF-10A cells. Carcinogenesis 2007; 28:1003-12; PMID:16909102; http://dx.doi.org/10.1093/carcin/bgl196

86. Rubbini C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Yasun A, Yoshida M, Wang XF, Yao P. HDAC6 is a microtubule-associated deacetylase. Nature 2002; 417:455-8; PMID:12424216; http://dx.doi.org/10.1038/417455a

87. Nadeem L, Brikc J, Chen YF, Bui T, Munir S, Peng C. Cytoskeletal reorganisation in the rapamycin pathway in ovarian clear cell adenocarcinoma. Int J Cancer 2014; 135:2019-29; PMID:24698177; http://dx.doi.org/10.1002/ijc.28117

88. Le XF, Pruefer F, Bast RC, Jr. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle 2005; 4:87-95; PMID:15611642; http://dx.doi.org/10.4161/cc.4.1.1360

89. Wanatabe A, Suzuki H, Yokobori T, Tsuigakohi M, Ahan B, Kubo N, Suzuki S, Araki K, Wada S, Kashibara K et al. Stathmin1 regulates p27 expression, proliferation and drug resistance, resulting in poor clinical prognosis in cholangiocarcinoma. Cancer Sci 2014; 105:905-13; PMID:24709182; http://dx.doi.org/10.1111/csc.12417

90. Akhtar J, Wang Z, Zhang ZP, Bi MM. Centrosomal-mediated RNA interference targeting stathmin1 gene in human gastric cancer cells inhibits proliferation in vitro and tumor growth in vivo. J Transl Med 2013; 11:212; PMID:23404910; http://dx.doi.org/10.1186/1477-5973-11-212

91. Knight LM, Stakaytis G, Wood JJ, Abdulla HA, Griffiths DA, Howells DJ, Wheat R, Blair GE, Steven NM, MacDonald A et al. Mekel cell polyomavirus...
small T antigen mediates microtubule destabilization to promote cell motility and migration. J Virol 2015; 89:55-47; PMID:25320307; http://dx.doi.org/10.1128/JVI.02517-14

102. Li N, Jiang P, De W, Wu Z, Li C, Qiao M, Yang X, Wu M. Siva1 suppresses epithelial-mesenchymal transition and metastasis of tumor cells by inhibiting stathmin and stabilizing microtubules. Proc Natl Acad Sci U S A 2011; 108:12851-6; PMID:21768358; http://dx.doi.org/10.1073/pnas.1017372108

103. Akhtar J, Wang Z, Yu C, Li CS, Shi YL, Liu HJ. STMN-1 is a potential marker of lymph node metastasis in distal esophageal adenocarcinomas and silencing its expression can reverse malignant phenotype of tumor cells. BMC Cancer 2014; 14:28; PMID:24433541; http://dx.doi.org/10.1186/1471-2407-14-28

104. Tan HT, Wu W, Ng YZ, Zhang X, Yan B, Ong CW, Li N, Jiang P, Du W, Wu Z, Li C, Qiao M, Yang X, Wang HS, Wu JC. HYS-32-Induced Microtubule Catastrophes in Rat Astrocytes Involves the PI3K-Akt-Mycin derivative RAD inhibits mesangial cell migration through the CDK-inhibitor p27Kip1. Lab Investig; J Tech Methods Pathol 2012; 84:432-43; PMID:23093784; http://dx.doi.org/10.1038/labinvest.3700087

105. LinX, Liao Y, Xie J, Liu S, Zou H. Op18/stathmin is revealed as a player in cancer cell migration and prognostic marker. J Proteome Res 2012; 11:1453-45; PMID:22181802; http://dx.doi.org/10.1021/pr3010956

106. Chiu CT, Liao CK, Shen CC, Liu SJ, Huang SF, Liu YH. Siva1 regulates keratinocyte proliferation and migration during cutaneous regeneration. PloS One 2013; 8: e75075

107. Daniel C, Pippin J, Shankland SJ, Hugo C. The rapamycin derivative RAD inhibits mesangial cell migration by down-regulating MnSOD in a STAT3-dependent manner. J Cell Sci 2014; 127:2920-33; PMID:25064772; http://dx.doi.org/10.1038/jcb.2013.28

108. Li S, Jiang P, Chen HJ, Poon M, Marks AR, Rabani LE. Role for p27(Kip1) in vascular smooth muscle cell migration. Circulation 2001; 103:2967-72; PMID:11413088; http://dx.doi.org/10.1161/01.CIR.103.24.2967

109. Zhang B, Ji LH, Liu W, Zhao G, Wu SY. Skp2-RNAi suppresses proliferation and migration of gallbladder carcinoma cells by enhancing p27 expression. World J Gastroenterol: WJG 2013; 19:4917-24; PMID:23946596; http://dx.doi.org/10.3748/wjg.v19.i30.4917

110. Daniel C, Pippin J, Shankland SJ, Hugo C. The rapamycin derivative RAD inhibits mesangial cell migration through the CDK-inhibitor p27Kip1. Lab Invest; J Tech Methods Pathol 2012; 84:432-43; PMID:23093784; http://dx.doi.org/10.1038/labinvest.3700087

111. Goukassian D, Diez-Juan A, Asahara T, Schratzberger PM,1017372108

112. Sun J, Marx SO, Chen HJ, Poon M, Marks AR, Rabani LE. Role for p27(Kip1) in vascular smooth muscle cell migration. Circulation 2001; 103:2967-72; PMID:11413088; http://dx.doi.org/10.1161/01.CIR.103.24.2967

113. Zhang B, Ji LH, Liu W, Zhao G, Wu SY. Skp2-RNAi suppresses proliferation and migration of gallbladder carcinoma cells by enhancing p27 expression. World J Gastroenterol: WJG 2013; 19:4917-24; PMID:23946596; http://dx.doi.org/10.3748/wjg.v19.i30.4917

114. Zhang D, Wang Y, Liang Y, Zhang M, Wei J, Zheng X, Li F, Meng Y, Zhu NW, Li J, et al. Loss of p27 up-regulates MoSKID in a STAT3-dependent manner, disrupts intracellular redox activity and enhances cell migration. J Cell Sci 2014; 127:2920-33; PMID:24727615; http://dx.doi.org/10.1242/jcs.148130

115. McEvoy F, Darbandi R, Chen SL, Eckard L, Dodd K, Jones K, Baucum AJ 2nd, Gibbons JA, Lin SH, Colbran RJ, et al. Metabolic regulation of CaMKII phosphorylation mechanism. J Biol Chem 1986; 261:8581-4; PMID:3722161

116. Schworer CM, Colbran RJ, Soderling TR. Reversible generation of a Ca2+-independent form of Ca2+-calmodulin-dependent protein kinase II by an auto-phosphorylation mechanism. J Biol Chem 1986; 261:8581-4; PMID:3722161

117. Strack S, Choi S, Lovinger DM, Colbran RJ. Transduction of autophosphorylated calcium/calmodulin-dependent protein kinase II to the postsynaptic density. J Biol Chem 1997; 272:13467-70; PMID:9159156; http://dx.doi.org/10.1074/jbc.272.21.13467

118. Cid C, Garcia-Bonilla L, Camafeira E, Burda J, Salinas M, Alcazar A. Proteomic characterization of protein phosphatase 1 complexes in ischemia-reperfusion and ischemia tolerance. Proteomics 2007; 7:3207-18; PMID:17683505; http://dx.doi.org/10.1002/pmic.200700214

119. Kim H, Claps G, Moller A, Bowell D, Lu X, Ronai ZA. Siah2 regulates tight junction integrity and cell polarity through control of ASPx2 stability. Oncogene 2014; 33:2004-10; PMID:23644657; http://dx.doi.org/10.1038/onc.2013.149

120. Twomey E, Li Y, Lei J, Sudja C, Ribeiro-Lukiewicz M, Smith B, Fang H, Bani-Yaghoub M, McKinnell I, Sikovska M. Regulation of MYPT1 stability by the E3 ubiquitin ligase SIAH2. Exp Cell Res 2010; 316:68-77; PMID:19744480; http://dx.doi.org/10.1016/j.yexcr.2009.09.001

121. Weigel B, Peterse JL, van ’t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005; 5:591-602; PMID:16056258; http://dx.doi.org/10.1038/nrc1670

122. Polekhina G, House CM, Tzafidic N, Mackay JP, Relaix F, Sassoon DA, Parker MW, Bowtell DD. Siah ubiquitin ligase is structurally related to TRAF and modulates TNF-alpha signaling. Nat Struct Biol 2002; 9:68-75; PMID:11742436; http://dx.doi.org/10.1038/nsb747

123. Siemesier G, Lucking U, Wengert AM, Liener P, Steinke W, Scharz C, Mumberg D, Ziegelbauer K. BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in monoclonal and in combination treatment upon oral application. Mol Cancer Therap 2012; 11:2205-73; PMID:22821149; http://dx.doi.org/10.1158/1535-7163.MCT-12-0286

124. Adam MG, Berger C, Feldner A, Yang WJ, Wutheube-Lauch J, Herberich SE, Pinder M, Gesierich S, Hammers HP, Augustin HG, et al. Synaptopo1-2 binding protein stabilizes the Notch ligands DLL1 and DLL4 and inhibits sprouting angiogenesis. Carc Res 2013; 115:1206-18; PMID:24025447; http://dx.doi.org/10.1111/circres.12068